Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of 6‑month vs 3‑month leuprorelin depot in premenopausal postoperative hormone‑therapy–naive breast cancer
jRCT2080221720Phase 3
- Sponsor
- Takeda
- Start
- Feb 2012
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of leuprolide in breast cancer (2 arms), sponsored by Takeda. Primary endpoints: Pharmacokinetics of TAP-144-SR(6M) vs TAP-144-SR(3M), Hormone level suppression and 2 more.
02
Drugs
leuprolide
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080221720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221720.